{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"number of patients that were still alive and relapse free","groups":[{"description":"peripheral blood lymphocyte therapy: T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be \\>0.5 x 105 but \\<1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be \\>2 x 106 cells/kg.\n\ncyclophosphamide: Cyclophosphamide 60 mg/kg/d for 2 days on Day -5 and Day -4\n\ntacrolimus: tacrolimus on day -1 administered by continuous IV infusion over 24 hours\n\nallogeneic hematopoietic stem cell transplantation\n\nperipheral blood stem cell transplantation\n\ntotal-body irradiation (TBI): Treatment will be delivered using 6MV photons twice daily for 3 days","id":"OG000","title":"T-Cell Depletion Transplant"}],"paramType":"NUMBER","populationDescription":"All patients that received treatment","reportingStatus":"POSTED","timeFrame":"after 7 years of follow up","title":"Number of Participants With Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"participants"}